Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Warrant (NQ:LEXXW)

0.1701 -0.0102 (-5.66%)
Streaming Delayed Price Updated: 1:17 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lexaria Bioscience Corp. - Warrant

< Previous 1 2 3 4 5 6 7 Next >
Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company
Via ACCESS Newswire
Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
Via ACCESS Newswire
Lexaria Announces $2 Million Registered Direct Offering of Common Stock
Via ACCESS Newswire
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience’s Technology
Via ACCESS Newswire
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Via ACCESS Newswire
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
Via ACCESS Newswire
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Via ACCESS Newswire
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Via ACCESS Newswire
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Via ACCESS Newswire
Lexaria's Human GLP-1 Study #5 Begins Dosing
Via ACCESS Newswire
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
Via ACCESS Newswire
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
Via ACCESS Newswire
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Via ACCESS Newswire
Lexaria Releases Annual Letter from the CEO
Via ACCESS Newswire
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
Via ACCESSWIRE
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Via ACCESSWIRE
Lexaria Forms New Scientific Advisory Board
Via ACCESSWIRE
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Via ACCESSWIRE
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
Via ACCESSWIRE
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Via ACCESSWIRE
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
Via ACCESSWIRE
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
Via ACCESSWIRE
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
Via ACCESSWIRE
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Via ACCESSWIRE
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
Via ACCESSWIRE
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.